Table 2.
Patient outcomes of crude and propensity score (PS)-matched cohorts
| Crude | After PS match | |||||||
|
TZ (N=1005) |
NT (N=11 055) |
Total (N=12 060) |
P value |
TZ (N=1005) |
NT (N=2010) |
Total (N=3015) |
P value | |
| Months after surgery | 0.0881* | 0.2018* | ||||||
| N | 1005 | 11 055 | 12 060 | 1005 | 2010 | 3015 | ||
| Mean (SD) | 36.9 (25.15) | 35.5 (25.59) | 35.6 (25.55) | 36.9 (25.15) | 35.7 (25.67) | 36.1 (25.50) | ||
| Median | 30 | 29 | 29 | 30 | 29 | 29 | ||
| (IQR) | (18.0, 50.0) | (16.0, 49.0) | (16.0, 49.0) | (18.0, 50.0) | (16.0, 50.0) | (17.0, 50.0) | ||
| DM(E10-E14, A10) | 10 (1.0%) | 89 (0.8%) | 99 (0.8%) | 0.5228* | 10 (1.0%) | 20 (1.0%) | 30 (1.0%) | 1.0000* |
| HT(I10-I15, C03, C07-C09) | 55 (5.5%) | 317 (2.9%) | 372 (3.1%) | <.0001* | 55 (5.5%) | 90 (4.5%) | 145 (4.8%) | 0.2287* |
| DL(E78, C10) | 50 (5.0%) | 239 (2.2%) | 289 (2.4%) | <.0001* | 50 (5.0%) | 62 (3.1%) | 112 (3.7%) | 0.0097* |
| Diuretics(C03) | 205 (20.4%) | 784 (7.1%) | 989 (8.2%) | <.0001* | 205 (20.4%) | 299 (14.9%) | 504 (16.7%) | 0.0001* |
| Frosemide(C03C A01) | 178 (17.7%) | 628 (5.7%) | 806 (6.7%) | <.0001* | 178 (17.7%) | 266 (13.2%) | 444 (14.7%) | 0.0011* |
| Spironolactone(C03DA01) | 61 (6.1%) | 225 (2.0%) | 286 (2.4%) | <.0001* | 61 (6.1%) | 105 (5.2%) | 166 (5.5%) | 0.3372* |
| Tolvaptan(C03XA01) | 3 (0.3%) | 8 (0.1%) | 11 (0.1%) | 0.0230* | 3 (0.3%) | 3 (0.1%) | 6 (0.2%) | 0.3860* |
| BB(C07) | 29 (2.9%) | 173 (1.6%) | 202 (1.7%) | 0.0018* | 29 (2.9%) | 31 (1.5%) | 60 (2.0%) | 0.0128* |
| Carvedirol(C07AG02) | 7 (0.7%) | 26 (0.2%) | 33 (0.3%) | 0.0074* | 7 (0.7%) | 9 (0.4%) | 16 (0.5%) | 0.3755* |
| Bisoprorol(C01AA05) | 1 (0.1%) | 6 (0.1%) | 7 (0.1%) | 0.5687* | 1 (0.1%) | 2 (0.1%) | 3 (0.1%) | 1.0000* |
| RAS(C09) | 45 (4.5%) | 304 (2.7%) | 349 (2.9%) | 0.0018* | 45 (4.5%) | 63 (3.1%) | 108 (3.6%) | 0.0614* |
| Captopril(C09AA01) | 2 (0.2%) | 16 (0.1%) | 18 (0.1%) | 0.6696* | 2 (0.2%) | 3 (0.1%) | 5 (0.2%) | 0.7516* |
| Enarapril(C09AA02) | 5 (0.5%) | 15 (0.1%) | 20 (0.2%) | 0.0070* | 5 (0.5%) | 3 (0.1%) | 8 (0.3%) | 0.0797* |
| Amiodarone(C01BD01) | 1 (0.1%) | 5 (0.0%) | 6 (0.0%) | 0.4601* | 1 (0.1%) | 1 (0.0%) | 2 (0.1%) | 0.6170* |
| Digoxin(C07AB07) | 17 (1.7%) | 78 (0.7%) | 95 (0.8%) | 0.0007* | 17 (1.7%) | 16 (0.8%) | 33 (1.1%) | 0.0259* |
| Death | 19 (1.9%) | 111 (1.0%) | 130 (1.1%) | 0.0092* | 19 (1.9%) | 53 (2.6%) | 72 (2.4%) | 0.2058* |
| Death (18mo) | 4 (0.4%) | 27 (0.2%) | 31 (0.3%) | 0.3566* | 4 (0.4%) | 10 (0.5%) | 14 (0.5%) | 0.7048* |
| CHF | 44 (4.4%) | 132 (1.2%) | 176 (1.5%) | <.0001* | 44 (4.4%) | 48 (2.4%) | 92 (3.1%) | 0.0027* |
| CHF (18mo) | 33 (3.3%) | 82 (0.7%) | 115 (1.0%) | <.0001* | 33 (3.3%) | 28 (1.4%) | 61 (2.0%) | 0.0005* |
| Events/n | 33/1005 | 82/11055 | 115/12060 | <.0001† | 33/1005 | 28/2010 | 61/3015 | 0.0009† |
| HR (95% CI) | 4.32 (2.88 to 6.47) | Reference | 2.28 (1.38 to 3.77) | Reference | ||||
*Chi-square p value.
†Logrank p value.
BB, beta-blocking agents; CHF, congestive heart failure; Death, all-cause deaths; Death (18 months), all-cause deaths within 18 months post-surgery; DL, dyslipidaemia; DM, diabetes mellitus; RAS, angiotensin-converting enzymes or angiotensin II receptor blocking agents.